MDS Virtual Congress 2020

September 12-16, 2020. Virtual Congress. www.mdscongress.org

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis

J. Ferreira, W. Poewe, A. Antonini, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Lisbon, Portugal)
Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study

H. Reichmann, A. Lees, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Dresden, Germany)
Opicapone in fluctuating Parkinson’s disease: The daily clinical practice

L. Armengou Garcia, G. Martí-Andrés, R. Valentí Azcárate, I. Esparragosa Vázquez, C. Toledano Illán, R. Villino Boquete, R. Luquin (Pamplona, Spain)
Opicapone in Parkinson’s disease – a centre’s real-life experience

F. Carvalho, J. Silva, J. Araújo, M. Rodrigues (Braga, Portugal)
Opicapone management: A 2-year follow up real- life practice study

M. Mata, C. Borrue, M. Almarcha (Madrid, Spain)
Opicapone study in daily clinical practice. OPRA study

J. Abril Jaramillo, J. Rodriguez, H. Perez (Sevilla, Spain)
Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II

G. Ebersbach, J. Ferreira, A. Antonini, A.T Santos, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Beelitz, Germany)
Optic atrophy and parkinsonism in a family associated with OPA1 mutation

Y.T Hsu, S.P Liu, W.D Lin, C.H Tsai (Taichung, Taiwan)
Oral treatment of the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) with the neuro-inflammation inhibiting compound PRI-003

J. Post-Schulz, A. Schaffrath, A. Willuweit, D. Willbold, J. Kutzsche (Jülich, Germany)
Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics

M.J Peterschmitt, T. Gurevich, T. Gasser, H. Saiki, S. Isaacson, C. Waters, A.M Wills, S. Hassin-Baer, T. Simuni, N. Hattori, S. Gaemers, S.P Sardi, S. Saubadu, P. Minini, T. Fischer (Cambridge, MA, USA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z